Loading clinical trials...
Loading clinical trials...
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Conditions
Interventions
Zanamivir
Placebo to match zanamivir
+2 more
Locations
170
United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Chula Vista, California, United States
GSK Investigational Site
Escondido, California, United States
GSK Investigational Site
Fullerton, California, United States
GSK Investigational Site
La Jolla, California, United States
Start Date
January 15, 2011
Primary Completion Date
March 18, 2015
Completion Date
March 18, 2015
Last Updated
October 15, 2018
NCT06355232
NCT06622590
NCT05227001
NCT05446740
NCT06602531
NCT05823974
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions